Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received approval for a supplemental new drug application (sNDA) in Taiwan for its influenza treatment and prophylaxis drug, Xofluza (baloxavir marboxil). This first-in-class, oral anti-viral medication is now approved for use in children aged between 5 to 12 years old, weighing at least 20 kilograms, for both treatment and postexposure prophylaxis against the influenza virus.
Xofluza has already been approved in Taiwan for adults and children aged 12 years and above as a treatment for acute infection by the influenza A or B virus and for postexposure prophylaxis of influenza. Originally discovered by Shionogi, the drug was licensed to the Swiss pharmaceutical giant Roche for global development in markets outside of Japan and Taiwan. – Flcube.com
